Word

DECISION MEDICINE

Status

Pending

Status Code

730

Status Date

Thursday, February 1, 2024

Serial Number

97441959

Mark Type

4000

Filing Date

Friday, June 3, 2022

Published for Opposition

Tuesday, June 13, 2023

Trademark Owner History

Pillar Biosciences, Inc. - Owner At Publication

Classifications

9 Downloadable software for the collection, management, and analysis of data acquired through nucleic acid sequencing, including next-generation sequencing (NGS), to inform healthcare decisions; downloadable software for the collection, management, and analysis of data for use in the fields of scientific research, clinical research, diagnostic research, and diagnostics; downloadable software for analyzing biological samples; downloadable software for analyzing biological samples for medical purposes, namely, for the screening, diagnosing, treating, and monitoring for recurrence of cancer and other diseases; downloadable software for use with reagents and reagent kits, all for the purpose of detecting, sequencing, and analyzing nucleic acids and other biological molecules, samples of biological molecules, genes, genomes, nucleotide sequence variants and modifications, all in the fields of scientific research, clinical research, diagnostic research, and diagnostics; downloadable software for bioinformatics and gene expression microarray image analysis, namely, gene expression quantification, gene image processing, and gene information processing; downloadable software for health and wellness assessment, namely, for use in genomic analysis; downloadable software for genetic and bioinformatics analysis; downloadable software for testing deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) molecules for research purposes; downloadable software for testing DNA and RNA molecules for diagnostic purposes; downloadable software for use in the fields of nucleic acid sequencing, genotyping, scientific research, clinical research, diagnostics research, and diagnostics; downloadable software for bioinformatics analysis of information derived through NGS; downloadable software for discovering and monitoring indicators of disease through analysis of sequencing data; downloadable software for detecting the presence and prevalence of cancer molecules and molecules indicative of other diseases through analysis of sequencing data; downloadable software for selecting appropriate therapies for disease treatment and management; downloadable software for developing companion diagnostics (CDx) for disease treatment and management

35 Data processing services for medical, clinical, and scientific purposes; data processing services, namely, analysis of sequencing data to detect the presence and prevalence of cancer molecules and molecules indicative of other diseases; management services, namely, management of business information and insights learned through analysis of the information relating to therapeutic medicine marketability

44 Providing localized nucleic acid sequencing for more actionable data to inform healthcare decisions; providing biological sample testing services for others in the field of medical diagnostics; providing biological sample testing services for others for medical purposes, namely, for the screening, diagnosing, treating, and monitoring for recurrence of cancer and other diseases; providing reagent sample testing and diagnostic services for others, namely, detecting, sequencing, and analyzing nucleic acids and other biological molecules, samples of biological molecules, genes, genomes, nucleotide sequence variants and modifications, all in the field of diagnostics; genetic testing for medical purposes; medical testing for diagnostic and treatment purposes; consulting services for medical purposes, health and wellness assessment services; providing health and wellness information; medical services, namely, diagnostic testing for the presence of cancer molecules and molecules indicative of other diseases in bodily fluids; diagnostic testing relating to human health; medical testing services relating to the screening, diagnosing, treating, and monitoring for recurrence of disease; selecting therapies for disease treatment and management; developing companion diagnostics (CDx) for disease treatment and management; management services, namely, management of medical information learned through nucleic acid sequencing, including next-generation sequencing (NGS), and information gathered through analysis of the medical information

42 Software as a service (SaaS), namely, hosting non-downloadable software for use by others for collecting, managing, and analyzing data acquired through nucleic acid sequencing, including next-generation sequencing (NGS), to inform healthcare decisions; SaaS, namely, hosting non-downloadable software for use by others for collecting, managing, and analyzing data in the fields of scientific research, clinical research, diagnostic research, and diagnostics; SaaS, namely, hosting non-downloadable software for use by others for analyzing biological samples; SaaS, namely, hosting non-downloadable software for use by others for analyzing biological samples for medical purposes, namely, for the screening, diagnosing, treating, and monitoring for recurrence of cancer and other diseases; SaaS, namely, hosting non-downloadable software for use by others with reagents and reagent kits, all for the purpose of detecting, sequencing, and analyzing nucleic acids and other biological molecules, samples of biological molecules, genes, genomes, nucleotide sequence variants and modifications, all in the fields of scientific research, clinical research, diagnostic research, and diagnostics; SaaS, namely, hosting non-downloadable software for use by others for bioinformatics and gene expression microarray image analysis, namely, gene expression quantification, gene image processing, and gene information processing; SaaS, namely, hosting non-downloadable software for health and wellness assessment, namely, for genomic analysis; SaaS, namely, hosting non-downloadable software for genetic and bioinformatics analysis; SaaS, namely, hosting non-downloadable software for selecting appropriate therapies for disease treatment and management; SaaS, namely, hosting non-downloadable software for developing companion diagnostics (CDx) for disease treatment and management; bioinformatics services, namely, product research and development in the field of bioinformatics; data processing services for medical, clinical, and scientific purposes; developing diagnostic testing models for others for medical, clinical, and scientific purposes; genetic testing for scientific research purposes; scientific consulting relating to scientific research; scientific services, namely, detection and analysis of cancer molecules and molecules indicative of other diseases in bodily fluids; scientific, clinical, and diagnostic research in the field of bioinformatics; scientific, clinical, and diagnostic research in the fields of disease detection and management; scientific, clinical, and diagnostic research in the fields of cancer discovery, cancer management, and therapy efficacy

"MEDICINE"

Trademark Events

Feb 3, 2024

Notice Of Approval Of Extension Request E-Mailed

Feb 1, 2024

Sou Extension 1 Granted

Feb 1, 2024

Sou Extension 1 Filed

Feb 1, 2024

Sou Teas Extension Received

Aug 8, 2023

Noa E-Mailed - Sou Required From Applicant

Jun 13, 2023

Official Gazette Publication Confirmation E-Mailed

Jun 13, 2023

Published For Opposition

May 24, 2023

Notification Of Notice Of Publication E-Mailed

May 10, 2023

Approved For Pub - Principal Register

May 9, 2023

Examiner's Amendment Entered

May 9, 2023

Notification Of Examiners Amendment E-Mailed

May 9, 2023

Examiners Amendment E-Mailed

May 9, 2023

Examiners Amendment -Written

May 5, 2023

Teas/Email Correspondence Entered

May 5, 2023

Correspondence Received In Law Office

May 5, 2023

Teas Response To Office Action Received

Nov 9, 2022

Notification Of Non-Final Action E-Mailed

Nov 9, 2022

Non-Final Action E-Mailed

Nov 9, 2022

Non-Final Action Written

Oct 26, 2022

Assigned To Examiner

Jun 13, 2022

New Application Office Supplied Data Entered

Jun 7, 2022

New Application Entered